In contrast to gene fusions involving protein kinases, such as the BCR-ABL fusion in chronic myeloid leukemia [21], therapeutic targets for cancers harboring gene fusion involving transcription factors are more elusive owed to their complex functions, as shown in this study. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.